- A completed definitive agreement was anticipated on or about Dec. 15, 2017
- The transaction is expected to close in February of 2018.
- The company will have approximately 24.4 million common shares and approximately 3.5 million warrants and options outstanding, with approximately $5-million in working capital.
- Canntab, a private Canadian company, has developed a patent-pending oral sustained-release formulation for cannabinoids.
Bi-layered tablets
Can Tab has developed unique bi-layered tablets that offer an immediate dosage and therefore immediate release of active ingredients, combined with our patent-pending extended release formulations. This is a step forward for patients offering the best of both worlds – both immediate and extended relief. As with their XR tablets, each bi-layered tablet contains a uniform dosage, available in different levels, making it easier for doctors and patients alike to find and manage dosage levels that work best for individual patients.
Gel Capsules
Canntab Therapeutics Gel Capsules offer doctors and patients a uniform amount of THC/CBD oil extract, in a quick dissolving gel capsule offering immediate relief from symptoms. As with all of their products, gel capsules are available in varying dosage levels, with each capsule containing the exact same amount of active ingredient for easy management.
Flash-Melt Tablets
Their flash melts are designed to dissolve immediately when placed under the tongue. They deliver an immediate dosage to the patient, offering instant relief. Their flash melt products are offered in different formulations depending on the medical need and have a uniform dosage offering the medical advantages of all their other products.